Form 4: Amneal Legal Officer's Stock Vesting & Tax Sales

Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, reported the vesting of restricted stock units and subsequent sales to cover tax obligations.

Summary

• Jason B. Daly, EVP, Chief Legal Officer of Amneal Pharmaceuticals, Inc., reported multiple transactions involving Class A Common Stock on March 3 and March 4, 2026.
• These transactions primarily involved the vesting of various grants of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs).
• On March 3, 2026, a total of 491,000 shares were acquired through the vesting of RSUs and PBRSUs.
• A significant portion of these acquisitions, 305,810 shares, resulted from performance-based restricted stock units granted on March 3, 2023, which vested at 200% of the targeted number due to achieving specific average closing prices over a three-year period.
• To satisfy tax withholding obligations related to these vestings, a total of 169,061 shares were disposed of at a price of $13.31 per share on March 3, 2026.
• On March 4, 2026, an additional 35,880 shares were acquired through RSU vesting, and 15,580 shares were disposed of at $13.30 per share for tax withholding.
• Following these transactions, Jason B. Daly's direct beneficial ownership of Class A Common Stock increased to 251,784 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event for the executive, reflecting successful vesting of equity awards, particularly the performance-based units at 200% of target. For the company, it's a neutral event, representing routine executive compensation.

Positives

• Performance-based restricted stock units vested at 200% of the targeted number, indicating strong achievement of performance thresholds related to the Issuer's Class A Common Stock average closing prices.
• The vesting of a substantial number of restricted stock units and performance-based units reflects the executive's continued equity participation and alignment with shareholder interests.

Negatives

• A significant number of shares (169,061 on March 3, 2026, and 15,580 on March 4, 2026) were disposed of to cover tax withholding obligations, which represents a reduction in the executive's direct ownership from the gross vested amount.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine Form 4 filings detailing executive stock vesting and tax-related sales are common across all industries for publicly traded companies. These transactions reflect standard executive compensation practices and do not typically indicate broader industry trends or competitive shifts.

Related Party Transactions

• The reported transactions are related party transactions as they involve an executive officer of Amneal Pharmaceuticals, Inc. acquiring and disposing of company stock. Specifically, these are equity compensation vestings and subsequent tax-related sales.

Stakeholder Impact

• Shareholders: The vesting of performance-based units at 200% of target could be viewed positively as it indicates the company met specific stock price performance thresholds, aligning executive incentives with shareholder value creation. The sale of shares for tax purposes is a routine event and generally has minimal impact on the broader market.
• Employees: The vesting of equity awards for a senior executive can serve as a positive signal regarding the company's compensation structure and potential for long-term incentives.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Form 4, Insider Trading, Restricted Stock Units, Performance-Based RSUs, Stock Vesting, Tax Withholding, Executive Compensation, Jason B. Daly